Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Lambda-1a ± Daclatasvir vs Peginterferon Alfa-2a with Ribavirin in Naive Genotype 2/3 Chronic Hepatitis C (Japan)
jRCT2080221960Phase 3
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic hepatitis C (CHC) comparing Peginterferon lambda-1a + ribavirin + placebo, Peginterferon lambda-1a + ribavirin + daclatasvir and Peginterferon alfa-2a + ribavirin + placebo (3 arms).
02
Drugs
peginterferon lambda-1a
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on jRCT2080221960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221960.